Patterns of practice for adaptive and real-time radiation therapy (POP-ART RT) part I: intra-fraction breathing motion management. by Anastasi, Gail et al.
Journal Pre-proofs
Original Article
Patterns of practice for adaptive and real-time radiation therapy (POP-ART
RT) part I: intra-fraction breathing motion management
Gail Anastasi, Jenny Bertholet, Per Poulsen, Toon Roggen, Cristina Garibaldi,
Nina Tilly, Jeremy T Booth, Uwe Oelfke, Ben Heijmen, Marianne C Aznar
PII: S0167-8140(20)30343-1
DOI: https://doi.org/10.1016/j.radonc.2020.06.018
Reference: RADION 8382
To appear in: Radiotherapy and Oncology
Received Date: 11 March 2020
Revised Date: 8 June 2020
Accepted Date: 12 June 2020
Please cite this article as: Anastasi, G., Bertholet, J., Poulsen, P., Roggen, T., Garibaldi, C., Tilly, N., Booth, J.T.,
Oelfke, U., Heijmen, B., Aznar, M.C., Patterns of practice for adaptive and real-time radiation therapy (POP-
ART RT) part I: intra-fraction breathing motion management, Radiotherapy and Oncology (2020), doi: https://
doi.org/10.1016/j.radonc.2020.06.018
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version
will undergo additional copyediting, typesetting and review before it is published in its final form, but we are
providing this version to give early visibility of the article. Please note that, during the production process, errors
may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier B.V.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
4
9
1
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
1
Patterns of practice for adaptive and real-time radiation therapy 
(POP-ART RT) part I: intra-fraction breathing motion 
management
Gail Anastasia*, Jenny Bertholetb*, Per Poulsenc, Toon Roggend, Cristina Garibaldie, Nina 
Tillyf, Jeremy T Boothg, Uwe Oelfkeb, Ben Heijmenh, Marianne C Aznari.
a St. Luke's Cancer Centre, Royal Surrey Foundation Trust, Radiotherapy Physics, Guildford, 
United Kingdom.
b1The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Joint 
Department of Physics, London, United Kingdom.
b2Division of Medical Radiation Physics, Department of Radiation Oncology, Inselspital, Bern 
University Hospital, Switzerland. Email:
cAarhus University Hospital, Department of Oncology and Danish Center for Particle Therapy, 
Aarhus, Denmark.
dVarian Medical Systems Imaging Laboratory GmbH, Applied Research, Dättwil AG, 
Switzerland.
eEuropean Institute of Oncology IRCCS, IEO- Unit of Radiation Research, Milan, Italy.
f1Elekta Instruments AB, Stockholm, Sweden. 
f2Medical Radiation Physics, Department of Immunology, Genetics and Pathology, Uppsala 
University, Uppsala, Sweden
gRoyal North Shore Hospital, Northern Sydney Cancer Centre, Australia.
hErasmus MC Cancer Institute, Department of Radiation Oncology, Rotterdam, Netherlands.
iDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of 
Manchester, The Christie NHS Foundation Trust, Manchester, UK and Nuffield Department 
of Population Health, University of Oxford
* Joint first authors
gail.distefano@nhs.net.  St. Luke's Cancer Centre, Royal Surrey Foundation Trust, 
Radiotherapy Physics, Guildford GU2 7XX, United Kingdom. 
jenny.bertholet@insel.ch. Present address: Division of Medical Radiation Physics, Department 
of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, CH-3010 
Bern, Switzerland.
2
Patterns of practice for adaptive and real-time radiation therapy 
(POP-ART RT) part I: intra-fraction breathing motion 
management
Gail Anastasia*, Jenny Bertholetb*, Per Poulsenc, Toon Roggend, Cristina Garibaldie, Nina 
Tillyf, Jeremy T Boothg, Uwe Oelfkeb, Ben Heijmenh, Marianne C Aznari.
aSt. Luke's Cancer Centre, Royal Surrey Foundation Trust, Radiotherapy Physics, Guildford, 
United Kingdom.
b1The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Joint 
Department of Physics-, London, United Kingdom.
b2Division of Medical Radiation Physics, Department of Radiation Oncology, Inselspital, Bern 
University Hospital, Switzerland
cAarhus University Hospital, Department of Oncology and Danish Center for Particle Therapy, 
Aarhus, Denmark.
dVarian Medical Systems Imaging Laboratory GmbH, Applied Research, Dättwil AG, 
Switzerland.
eEuropean Institute of Oncology IRCCS, IEO- Unit of Radiation Research, Milan, Italy.
f1Elekta Instruments AB, Stockholm, Sweden. 
f2Medical Radiation Physics, Department of Immunology, Genetics and Pathology, Uppsala 
University, Uppsala, Sweden
gRoyal North Shore Hospital, Northern Sydney Cancer Centre, Australia.
hErasmus MC Cancer Institute, Department of Radiation Oncology, Rotterdam, Netherlands.
iDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of 
Manchester, The Christie NHS Foundation Trust, Manchester, UK and Nuffield Department 
of Population Health, University of Oxford
* Joint first authors
3
Abstract
Purpose
The POP-ART RT study aims to determine to what extent and how intra-fractional real-time 
respiratory motion management (RRMM) and plan adaptation for inter-fractional anatomical 
changes (ART), are used in clinical practice and to understand barriers to implementation. Here 
we report on part I: RRMM 
Material and Methods
A questionnaire was distributed worldwide to assess current clinical practice, wishes for 
expansion or new implementation and barriers to implementation. 
RRMM was defined as inspiration/expiration gating in free-breathing or breath-hold, or 
tracking where the target and the beam are continuously realigned.
Results
The questionnaire was completed by 200 centres from 41 countries. RRMM was used by 68% 
of respondents (‘users’) for a median (range) of 2 (1-6) tumour sites. 
Eighty-one percent of users applied inspiration breath-hold in at least one tumour site (breast: 
96%). External marker was used to guide RRMM by 61% of users. KV/MV imaging was 
frequently used for liver and pancreas (with fiducials) and for lung (with or without fiducials). 
Tracking was mainly performed on robotic linacs with hybrid internal-external monitoring.
For breast and lung, approximately 75% of respondents used or wished to implement RRMM, 
which was lower for liver (44%) and pancreas (27%). Seventy-one percent of respondents 
wished to implement RRMM for a new tumour site. Main barriers were human/financial 
resources and capacity on the machine.
Conclusion
Sixty-eight percent of respondents used RRMM and 71% wished to implement RRMM for a 
new tumour site. The main barriers to implementation were human/financial resources and 
capacity on treatment machines.
Keywords: Image-guided radiotherapy, MR-guided radiotherapy, intra-fractional motion, 
gating, tumour tracking, breath hold, real-time respiratory motion management
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It is well documented that tumours in the thorax and abdomen are susceptible to respiratory 
motion [i,ii,iii,iv]. For “passive” motion management approaches, planning target volumes 
(PTV) are often defined by encompassing the entire tumour motion observed on a 4DCT 
(internal target volume (ITV) approach [v]) or by using a statistical margin recipe (e.g. mid-
ventilation approach [vi]). These approaches often result in large PTV volumes, which may lead 
to increased normal tissue toxicity or potentially hamper tumour dose intensification. In 
contrast, active real-time respiratory motion management (RRMM) approaches (i.e. gating or 
tracking) may increase targeting accuracy and allow a safe margin reduction and/or dose 
intensification [iii,vii,viii,ix,x]. Gating involves turning the beam on only when the target is in the 
desired location while the patient is in free-breathing (FB) or in breath-hold (BH). Tracking 
involves continuous beam-target realignment. For breast and lung cancer, inspiration BH also 
results in dosimetrically more favourable lung volume and target-to-heart separation [xi]. There 
is compelling evidence that RRMM improves the delivered dosimetric accuracy 
[vii,xii,xiii,xiv,xv]. This, combined with some evidence of improved clinical outcome [xvi,xvii,xviii], 
points to RRMM approaching standard of care for specific indications like left breast. The 
AAPM TG76 report recommends the use of active motion management whenever respiratory 
motion exceeds an amplitude of 5mm and/or if it can significantly improve OAR sparing or is 
needed to achieve clinical goals [xix]. This is especially desirable for SBRT where optimal OAR 
sparing is often required to allow dose intensification.
The use of respiratory gating to improve radiotherapy delivery in the treatment of mobile 
tumours was first described over 30 years ago [xx,xxi], but the dissemination of RRMM 
approaches has long been hampered by the lack of commercially available technology. Today, 
gating is feasible on the majority of beam delivery systems using breathing surrogates, but 
imposes a reduced duty cycle in free-breathing while BH requires patient compliance. Tracking 
is more time-efficient but more technically complex and is currently only commercially 
available on specialized platforms [xxii,xxiii]. MLC tracking on a conventional (C gantry) linac 
was demonstrated clinically for lung cancer patients in a research setting [xxiv]. Couch tracking 
may also be used to address respiratory motion but has not been demonstrated clinically to date 
[xxv]. Technical challenges for RRMM include handling the software/hardware connectivity 
such as the fast feedback loop to adapt the beam delivery settings, and also motion monitoring 
e.g. the uncertainty in correlation between surrogate and target motion, particularly for 
breathing surrogates [xxvi,xxvii,xxviii]. 
Current commercial RRMM solutions cover a wide range of combinations of monitoring 
signals and RRMM techniques depending on the available treatment platform, software and 
add-ons [xxvi]. Intra-fraction motion monitoring, a requirement for the implementation of 
RRMM, represents a substantial challenge in itself. Other challenges include additional 
hardware cost, workload and daily treatment time, the need for different QA procedures 
[xxix,xxx,xxxi] and appropriate staff and patient training. Though RRMM can be considered 
standard-of-care in some tumour sites (e.g. deep-inspiration breath-hold in left-sided breast 
cancer) [xxxii], it is unclear how many institutions have RRMM capabilities and how many 
patients are treated with RRMM today. Neither is there an overview of experienced hindrances 
and barriers. 
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The patterns of practice for adaptive and real-time radiation therapy (POP-ART RT) survey 
was designed to determine to which extent and how RRMM and Adaptive Radiotherapy (ART) 
are used in clinical practice in external beam photon RT. In addition, the survey aimed to 
identify the barriers to implementation or further use to help promote the safe and effective use 
of these methods as a standard of care. The present paper focuses on the first part of the survey:  
RRMM. The second part of the survey, focusing on ART for coping with inter-fractional 
changes taking place on a longer timescale [xxxiii] is the topic of an accompanying paper [xxxiv]. 
Materials and methods
Development of the survey started at the 2nd ESTRO physics workshop topic ‘Real-time and 
adaptive management of anatomical variation’ (Málaga, October 2018) that gathered clinical, 
research and industry physicists and one clinical oncologist. The clarity of the questions and 
completeness of multiple choice answers was improved with the help of three independent 
physicists (not present at the workshop). The final web-based questionnaire available as 
supplementary material was distributed and promoted via mailing lists, web articles and social 
media between February and July 2019 (see acknowledgements). Institutions that were not 
(yet) using RRMM/ART were explicitly encouraged to also respond and fill the “wish-list and 
barriers” questions.
Responding centres (“respondents” hereafter) were included in the analysis when they provided 
a complete response or only isolated questions had not been answered. Where there was no 
answer or when the authors were unable to interpret the answer, this was designated as “not 
specified” or “unknown”. 
Analysis and Definitions
Responding centres were asked if they were private, public and/or academic centres (with more 
than one choice possible, question (Q)3, page (p)3) and the number of patients treated with 
external RT per year (Q4, p3). Respondents were subsequently categorized into low volume 
(<1000 patients/year), medium volume (1000-2000 patients/year) and large volume (>2000 
patients/year) centres. The gross national income per capita (GNI/n) for the year 2018 [xxxv] 
was used to group respondents into low, middle and high income countries [xxxvi] (Q2, p3). 
RRMM was defined as the use of gating (FB or BH) or tracking defined as continuously 
realigning the target and the beam (via robotic, gimbal, MLC or couch tracking) (p4). 
Five RRMM techniques were considered (Q4, p7):
1) (deep) Inspiration Breath-hold
2) Expiration Breath-hold
3) Free-breathing inspiration gating
4) Free-breathing expiration gating
5) Tracking
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Responding centres using RRMM (‘users’ hereafter), were asked about patterns of practice 
(patient selection criteria Q1-2, p6 and workflow and technological approaches Q3-8, p7-10) 
for four main tumour sites, namely breast, lung, liver and pancreas, but were able to specify 
other sites.  
Wish-lists and barriers to implementation
Users were asked if they wished to increase the use of RRMM or modify their technique in the 
next two years (p11).  Barriers to implementation or further implementation were ranked in 
order of importance (Q2, p12).
Participants could select a barrier as not relevant for their institution by leaving its rank blank. 
All respondents (users and non-users) were asked if they wished to implement RRMM for any 
new tumour site (p13) and rank the same barriers to this.  
Results
The RRMM part of the questionnaire was completed by 200 institutions from 41 countries. 
There were no respondents from the low-income group and only 20 from the middle-income 
group (table A.1). Sixty-eight percent (136/200) of all respondents used RRMM for a median 
(range) of 2 (1-6) tumour sites (table 1). The most common sites were breast (111/200), lung 
(89/200), liver (62/200), pancreas (41/200) and lymphoma (14/200). In addition, three users 
reported using RRMM for ‘mediastinum’, two for ‘heart’,’ oesophagus’ or ‘abdomen’ and one 
user each for ‘thymoma’, ‘mesothelioma’, ‘adrenal’, ‘stomach’ or ‘suprarenal’ tumours. 
RRMM was more prevalent in high-income countries than middle-income countries and in 
academic centres compared to private and public centres (table A.2).
Within any given tumour site, users generally only applied RRMM in selected patients (figure 
1a). Most users applied RRMM for <25% of lung, pancreas and lymphoma patients, for 25-
50% of the breast patients and for >75% of the liver patients. Five users who indicated using 
RRMM for 100% of patients, commented that it was 100% of stereotactic body radiotherapy 
(SBRT) patients.
The main selection criteria reported for breast patients were ‘left breast’ (76%) and ‘heart 
dose/position’ (20%), while for lung, liver and pancreas, the main criteria were ‘SBRT’ (~50%) 
followed by ‘tumour motion amplitude’ (figure 1b).
Inspiration BH was the dominant technique among RRMM users for breast (96%), lymphoma 
(93%) and lung (38%) (figure 1a). Gating was performed on linacs, except for one user 
employing Tomotherapy (Accuray Inc, Sunnyvale, CA) for expiration gating (lung) and four 
users performing gating on an MR-linac. Fifteen percent of users were using tracking (figure 
1a) with a higher prevalence in private and academic centres than public ones (table A.2). 
Tracking is currently only commercially available on the Cyberknife (Accuray) or Vero 
(BrainLab and Mitsubishi Heavy Industries, Japan) platforms. Cyberknife was used by all 
tracking users except one which used a conventional linac as part of a clinical trial for 
7
electromagnetic-guided MLC tracking (lung) [xxiv]. For all other respondents who reported 
tracking on conventional linacs, we assumed they were monitoring tumour motion but not 
actually realigning the target and the beam in real-time. Their RRMM technique was 
designated as “unknown”. No Vero user responded to the survey. No centre from middle-
income countries reported tracking (table A.2, figure A.1). In the following, users who 
responded doing both gating and tracking for a given treatment site are considered as a separate 
group from gating only or tracking only because it was not possible to determine to which 
technique following responses applied.
Across all tumour sites and techniques, external marker (e.g. RPM) was the main RRMM 
signal, used by 61% of users (figure 2). For breast, surface imaging was used by 23% of users. 
KV/MV imaging was frequently used for liver and pancreas (with fiducials) and for lung (with 
or without fiducials). A hybrid RRMM technique was used by all Cyberknife users 
(Synchrony) [xv] and by one linac user for gating with the BrainLab beam delivery system 
[xxxvii]. No user from a middle-income country reported use of MR, surface or 
electromagnetic guidance for RRMM (figure A.2).
Under half of the users who employed surface imaging or a breathing surrogate (external 
marker, breathing volume, pressure belt), acquired verification images during beam-on (table 
A.3). However when acquired, verification images were generally looked at online.
A dedicated coaching session was used by over half of the users treating breast and lymphoma 
with gating (mostly <15mins, figure 3a). Audio and/or visual feedback was used by >70% of 
users for lymphoma and breast and by just above 50% of users for lung, liver and pancreas 
(figure 3b). Coaching and feedback were generally not used in combination with tracking 
(figure 3).
For breast and lung, 36% and 49% of respondents respectively wished to expand/change their 
technique or implement RRMM (figure 4a). For liver and pancreas >55% of respondents did 
not use RRMM and did not wish to implement it in priority, in contrast to <25% for breast and 
lung. Overall 71% of respondents wished to implement RRMM for a new treatment site (figure 
4b). In addition to the tumour sites mentioned in the survey, nine respondents wished to 
implement RRMM for abdominal sites and five for oesophagus. 
Sixty-four users ranked the barriers to further use of RRMM. Equipment/financial resources 
was ranked first or second by 34 respondents (first to third by all middle-income countries). 
Human resources and treatment machine capacity were also considered highly important by a 
majority of respondents. Although most respondents rated reimbursement as not relevant or 
having a low importance, 8% of respondents still rated it as the main limitation (figure 5).
The barriers to implementing RRMM for new tumour sites were ranked by 123 respondents. 
Human resources was almost equally important as equipment/financial resources followed by 
treatment machine capacity. Reimbursement remained lowly ranked. 
Barriers entered as other and comments on the barriers included ‘limited linacs with necessary 
equipment’ or ‘waiting for MR-linac’ (four respondents), ‘increased time for treatments’ (two 
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respondents), ‘lack of time to develop/implement new techniques’ (two respondentss), ‘multi-
disciplinary cooperation’ (two respondents), ‘patient compliance’ (two respondents), ‘lack of 
national target’ (one respondents), ‘approval from authorities’ (one respondent). 
The ranking of barriers did not differ substantially from the overall ranking when analysed by 
type of institution or socio-economic status although the number of responses was occasionally 
very small (figure A.3). 
Discussion
This study reports on the patterns of practice for RRMM in 200 RT centres from 41 countries 
worldwide. 
Sixty-eight percent of respondents used RRMM for at least one tumour site (table 1), with a 
median (range) number of tumour sites per user of 2 (1-6). Eighty-one percent of RRMM users 
applied inspiration BH in at least one tumour site. 
Despite our explicit definition of tracking as active realignment of the beam and the moving 
target, there was confusion among some respondents who indicated doing tracking on 
conventional linacs. Since this option is not commercially available, despite active research in 
the past decades [xxxviii,xxxix,xxv,xl], we attempted to contact those respondents who confirmed 
that they were only monitoring motion (visual tracking, as opposed to active beam/target re-
alignment). When the correct answer could not be confirmed (7 users), we indicated ‘unknown’ 
as the RRMM technique. It was confirmed that tracking was used in 10% of respondents while 
gating (BH or FB) was used by 62%.   
The proportion of patients being offered RRMM varied according to tumour site. For example, 
where RRMM was employed to treat liver tumours, it tended to be offered to a large proportion 
of patients (mode: >75%, figure 1a). In contrast, RRMM was mostly used for 25-50% of breast 
cancer patients and <25% of lung cancer patients (figure 1a). One explanation could be that, 
given a relatively small volume of liver patients, the workload remains manageable, while the 
larger patient volume for breast and lung necessitates stricter patient selection. 
At the time of data collection some clear patterns of practice were highlighted in this fast 
evolving field.  Inspiration BH was the dominant RRMM technique for breast and lymphoma, 
whereas the spread in technique was greater for other sites (figure 1a).  The reported selection 
criteria reflect the clinical evidence of heart-sparing in left-breast (Deep) Inspiration BH [xvi] 
and the need for higher targeting accuracy in SBRT [xii,xiii]. Note also that for lung, liver and 
pancreas, some users that indicated treating 100% of patients with RRMM specified that it was 
SBRT patients only. For lung cancer, SBRT is often used for small mobile tumours, while, for 
locally advanced lung cancer, the dosimetric impact of intrafractional motion (including 
respiration) is often smaller than that of large interfractional anatomical changes, which are 
addressed with ART [xxxiv].
Across all tumour sites, an external marker surrogate was the main RRMM signal used by 61% 
of users (figure 2). While kV/MV imaging was often reported, it was mostly in combination 
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with a breathing surrogate. It remains unclear if image-based monitoring was performed 
automatically or as visual verification for the breathing surrogate. To our knowledge, there is 
only one commercial solution available for gating on conventional linacs that combines 
automatic fiducial monitoring on kV images with external marker monitoring [xli].
Less than half of users employing a breathing surrogate acquired verification images during 
treatment. However, there is evidence that residual errors between breathing surrogates and 
internal target motion may be substantial [xlii,xliii,xliv,xlv]. This reflects the lack of practical intra-
fraction monitoring solutions for internal targets and the need to integrate such solutions into 
the clinical workflow. Daily pre-treatment assessment and correction of the mean tumour 
position, required for non-breast tumours [xlvi], was not covered by the questionnaire. 
Hybrid monitoring, where the external-internal correlation is explicitly considered and verified 
during delivery, was used for Cyberknife-based tracking, with markerless tumour motion 
monitoring for certain lung tumours [xvii].  
Over 75% of respondents wished to implement or change/increase their use of RRMM for lung 
and breast in priority whereas this was the case for only <50% of the respondents for liver and 
pancreas. Note that some of these respondents might not offer liver or pancreas RT at all. 
Respiratory motion amplitude is often larger in the abdomen compared to the thorax [i,ii,iii,iv] 
but motion monitoring is also more challenging due to poor soft tissue visualization on kV/MV 
imaging. MR-linacs provide better soft tissue contrast, facilitating RRMM in the abdomen, 
provided that motion mitigation is available [xlvii,xlviii]. 
Over 40% of respondents had plans to implement RRMM for a new treatment site within the 
next two years (figure 4b), meaning a significant rise in RRMM can be expected. Twenty-four 
percent of the respondents that already used RRMM for at least one treatment site had no wish 
to implement RRMM for a new treatment site. Only 3% of respondents were not users and had 
no wish to implement RRMM for any site. The main barriers of human/material resources are 
most likely due to the need for additional equipment which comes at significant cost and an 
increased need in staff to cover different platforms/equipment. Although this survey did not 
cover RRMM commissioning and QA in detail, their importance and associated added 
workload [xxix] cannot be underestimated, especially for centres implementing RRMM for the 
first time. Hardware QA was documented by De Los Santos et al [xxix], while treatment-
delivery QA such as automated 4D dose reconstruction has been demonstrated clinically (in 
real-time or offline) in research settings [viii,xlix]. Full verification of RRMM requires 
discretization of treatment delivery into small time-increments. This time-resolved evaluation 
process represents a paradigm shift in treatment verification. In contrast, verification for ART 
[xxxiv] can be performed on a per-fraction basis (e.g. using log-files, secondary dose 
calculation) where the delivered dose at each fraction can be evaluated in a similar manner as 
full-course plans.     
Of the 200 centres who completed the RRMM part of the questionnaire, 177 centres also 
completed the part covering ART [xxxiv]. Offline replanning, where plan verification can be 
performed essentially in the same way as for non-ART cases, was applied by 50% of 
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respondents. We encourage the reader to see the accompanying paper for expansion of common 
results and discussions [xxxiv].
With only twenty respondents from middle-income countries, it is difficult to draw conclusions 
based on socio-economic status. The human/material resources needed for ART/RRMM are 
expected to be less available in middle-income countries [l,li] which may explain why no 
respondent from middle-income countries used tracking or MR, surface or electromagnetic 
guidance to trigger gating. For ART[xxxiv], no respondents from middle-income countries was 
using daily online replanning which is also the most demanding in terms human/material 
resources.
A limitation for both parts of this study is the bias in the representation of respondents. Most 
respondents were public or academic centres in high-income countries. Centres doing or having 
an interest in RRMM/ART may have been more likely to respond, despite our encouragement 
to non-users to respond. This bias may have had a particularly strong impact for centres from 
middle-income countries. In addition, the survey was only available in English and was 
promoted and completed on the internet which may have resulted in a low number of responses 
from countries where English is not a commonly spoken language or where internet access is 
low. Other limitations include a) the subjectivity of the respondent for the wish-lists and 
barriers questions which may represent their personal assessment rather than the consensus 
opinion of the centre b) the survey was mostly addressed to physicists. Hospital administrators 
might have other views of the barriers. Nonetheless, we believe that with 135 users (108 for 
ART [xxxiv]), this study gives an interesting insight into how RRMM and ART are used 
currently as well as the wishes for expansion/changes. In addition with 65 non-users (69 for 
ART), the study provides important information on barriers to implementation
Based on our results, the required next steps to promote the safe and effective use of RRMM 
as a standard of care are:
1) that manufacturers provide practical, low-cost internal verification monitoring 
solutions for internal targets on conventional linacs, particularly where an external 
breathing surrogate is used.
2) that such solutions be integrated into the clinical workflow with minimal increase in 
treatment time and workload. 
3) that research studies providing evidence of improvement in clinical outcomes as direct 
result of RRMM are performed to support clinical relevance/interest. 
In conclusion, 68% of respondents used RRMM for at least one tumour site, primarily with 
gating (in free breathing or in breath-hold) using external marker. Although RRMM was 
common in the thorax, it was generally applied for less than half of the patients. Further, within 
the same tumour site, there is a large disparity among respondents with regards to the number 
of patients selected for RRMM. There is an unmet need for RRMM, particularly in lung cancer 
where 49% of respondents wished to expand or implement RRMM. More than 40% of the 
respondents have plans to implement RRMM within two years but the main barriers were 
human/material resources and machine capacity.  
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To further promote safe and effective use of both ART and RRMM and to reduce the strain on 
human/material resources, we recommend that users, future users and vendors work together 
towards efficient solutions and workflows available for use on conventional equipment. 
Further, consensus on best practice is needed for the establishment of clear, broadly accepted 
guidelines. This could also contribute to development of solid and consistent reimbursement 
practices.
Acknowledgements
We thank all the centres who have answered the survey for taking the time to provide complete 
and high-quality answers. We thank ESTRO for the organisation of the 2nd physics workshop, 
for logistics support and for disseminating the survey to their membership and to the national 
societies. 
We would like to thank Elisabetta Cagni, Jacqui Parker, and Michael Thomas for testing the 
survey. We thank Tominga Masahide, Sasaki Motoharu, Victoria Parra, Marc Pachoud, Kojima 
Takeshi, Sam Vinko, Paul Krechting, Peter Kimstrand, Samuel Fransson, Magali Edouard and 
Daniel Lambisto for their participation in elaborating the questionnaire.
We thank Lauren Wright and Michael Jones from the Institute of Cancer Research for their 
help with the analysis of the barriers.
Additional thanks go to the European Federation of Organisations For Medical Physics 
(EFOMP), the Canadian Organisation of Medical Physics (COMP), the Belgian Hospital 
Physicists Association (BHPA), the Associazione Italiana di Fisica Medica (AIFM), the 
Deutschen Gesellschaft für Medizinische Physik (DGMP), the Swedish association for 
radiophysics, Aunt Minnie Europe and Tami Freeman from Physics World, for advertising the 
survey on their websites.
JB acknowledges funding from the Stand Up to Cancer campaign for Cancer Research UK 
(C33589/A19727 and C33589/A19908) and the CRUK ART-NET Network Accelerator 
Award (A21993) as well as NHS funding to the NIHR Biomedical Research Centre at The 
Royal Marsden and The Institute of Cancer Research. 
GA acknowledges funding from the UK National Institute for Health Research (NIHR), 
(Doctoral Research Fellowship). The views expressed are those of the author(s) and not 
necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
MA acknowledges support from Cancer Research UK [grant no C8225/A21133], the NIHR 
Manchester Biomedical Research Centre and CRUK ART-NET Network Accelerator Award 
(A21993).
12
Figure 1: a) Fraction of users that use a given technique. The pattern of each column indicates 
the technique, The colour of each column segment indicates the percentage of patients 
receiving gated/tracked treatment. Respondents could use more than one technique per 
treatment site. A substantial number of respondents reported using tracking but it was unclear 
if tracking was meant as monitoring only. b) Fraction of users that use given selection criteria 
to decide to treat patients with gating or tracking. Respondents could use more than one 
criterion per treatment site.
Figure 2: Fraction of users that use a given signal to trigger the gating or control the tracking 
feedback loop (alone or in combination).
Figure 3: a) Fraction of users using gating or tracking that use a separate coaching session. b) 
Fraction of users doing gating or tracking that use audio and/or visual feedback to the patient.
Figure 4: a) Percentage of respondents using gating/tracking with (dark blue) and without 
(medium blue) a wish to change technique or increase the number of patients having 
gating/tracking, respondents not applying gating/tracking with (light blue) and without (grey) 
a wish to implement it. b) Overall percentage of respondents wishing to implement gating or 
tracking for any new treatment site (blue, green and yellow) or not (red).
Figure 5: Histogram of the barriers to further use for an existing RRMM tumour site (left) or 
implementation for a new tumour site (right). Colour indicating increase in importance from 
blue colour (low) towards red colour (high). The grey bars indicate the number of institutions 
that considered the barrier “not relevant”.
Figure A.1: Fraction of users that apply the defined types of RRMM. Data are presented for 
all users together (last column) and for subgroups defined by type of institution (private, public, 
academic) and income (middle or high-income).
 
Figure A.2: Fractions of users that use a given signal to trigger the gating or control the 
tracking feedback loop (alone or in combination) per type of institution and economic status. 
The results for the overall group are shown to the right.
Figure A.3: Histogram of ranks given to the barriers to further use or new implementation of 
RRMM by type of institution and economic status.
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Highlights 
 Real-time respiratory motion management (RRMM) practice, evaluated for 200 
centres.
 Sixty-eight percent of respondents used RRMM for at least one tumour site. 
 Across all tumour sites, external marker was the main RRMM signal used.
 Overall 71% of respondents wished to implement RRMM for a new treatment site. 
 The main barriers were human/financial resources and capacity on the machine.
Table 1: Percentage of all respondents (N=200) using gating or tracking to manage respiratory motion for specific treatment sites or overall. 
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Type of 
motion 
management
FB inspiration 
gating
[%]
FB expiration 
gating 
[%]
(deep) inspiration 
BH 
[%]
Expiration 
BH 
[%]
All gating
(FB/BH)
[%]
Tracking1 
[%]
Unknown2 
[%]
All including 
(excluding) 
unknown
[%]
Breast 1 0 53 <1 54 1 1 56 (55)
Lung 13 11 17 4 32 10 6 45 (39)
Liver 6 8 9 8 22 8 3 31 (29)
Pancreas 4 5 6 6 15 5 2 21 (19)
Lymphoma 0 0 7 <1 7 0 0 7   (7)
Any site 13 13 55 10 62 10 7 68 (65)
Abbreviations: BH = breath-hold, FB = free-breathing
1One respondent reported using MLC tracking in a trial, all other users used CyberKnife
2 For respondents reporting to do tracking on conventional linacs (without further explanation about the use of commercially unavailable technology), the 
authors assumed that tumour motion was monitored but that the beam was not realigned with the target. 
Table A.1: Characteristics of respondents. Number (percentage)
Type of institution1 Economic status2 
Group Overall N = 200 Private 
N = 52
Public 
N = 132
Academic 
N = 57
Middle-income
N = 20
High-income
N = 178
Small volume3 61 (31%) 25 (48%) 35 (27%) 5 (9%) 9 (45%) 50 (28%)
Medium volume3 68 (34%) 14 (27%) 46 (40%) 14 (25%) 6 (60%) 62 (35%)
Large volume3 69 (35%) 12 (23%) 51 (39%) 37 (65%) 4 (20%) 65 (37%)
1 Institution could specify more than one type.
2 Information unavailable for two institutions. The “middle-income” group included institutions from Egypt, Indonesia, India, the 
Philippines, Brazil, Ecuador, Mexico, Peru, Romania, Serbia, Russia and South Africa. The “high-income” group included 
institutions from Austria, Belgium, Switzerland, Czech republic, Germany, Denmark, Estonia, Spain, Finland, France, Great 
Britain, Croatia, Hungary, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Sweden, Slovenia , USA, Canada, Australia, 
Israel, Hong Kong and the Arab Emirates
3 Number of respondents with small (<1000 patients/year) / medium (1000-2000 patients/year) / large (>2000 patients/year) patient 
volume (external beam RT only). Two institutions did not specify the patient volume (numbers do not always add up to ‘N’).
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Table A.2: Percentages of all respondents that apply RRMM; overall and according to type of institution and economic status.
Type of institution3 Economic Status4Group Overall (N=200)
Private 
N = 52
Public 
N= 132
Academic 
N=57
Middle-income N=20 High-income N=178
Type of 
motion 
management
Tracking1
[%]
All2 
(unknown) 
[%]
Tracking1
[%]
All2 
(unknown)
[%]
Tracking1
[%]
All2 
(unknown) 
[%]
Tracking1
[%]
All2 
(unknown) 
[%]
Tracking1
[%]
All2 
(unknown) 
[%]
Tracking1
[%]
All2 
(unknown)
[%]
Breast 1 56 (1) 0 48 (2) <1 58 (<1) 2 74 (0) 0 30 (5) 1 59 (<1)
Lung 10 45 (5) 15 50 (10) 8 40 (5) 17 63 (4) 0 35 (15) 11 46 (5)
Liver 8 31 (3) 12 35 (6) 7 25 (2) 13 54 (2) 0 30 (5) 9 31 (2)
Pancreas 5 21 (2) 8 23 (4) 3 17 (2) 10 42 (2) 0 20 (0) 5 21 (2)
Lymphoma 0 7 (0) 0 4 (0) 0 8 (0) 0 15 (0) 0 0 0 8 (0)
Any site 10 68 (7) 15 62 (10) 8 68 (7) 17 88 (4) 0 45 (15) 11 70 (6)
1Tracking is for all respondents that had tracking in their reply (tracking only or tracking and gating).
2 All is for all respondents that had tracking only, tracking and gating or gating only in their reply.
3Institution could specify more than one type.
4 Information unavailable for two institutions. See Table A.1.
Table A.3: Number of users who take a verification image during treatment when using a breathing 
surrogate.
Do you take verification imaging during beam-on?
N (%)
Tumour 
site
N 
(breathing 
surrogate) 
Yes, we look at 
them online
Yes, we look at 
them offline
No Not specified
Breast 106 27 (25%) 17 (16%) 56 (53%) 6
16
Lung 72 28 (39%) 6 (8%) 37 (51%) 1
Liver 44 17 (39%) 2 (5%) 24 (55%) 1
Pancreas 31 14 (45%) 1 (3%) 15 (48%) 1
Lymphoma 14 2 (14%) 4 (28%) 8 (57%) 0
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